on november 9th, the groundbreaking ceremony of
the global r&d center of tot biopharm was successfully completed. among
attendees of the ceremony including mi shen, member of the standing committee
of the cpc suzhou municipal committee and secretary of the party working
committee of sip; jing shen, director of the suzhou municipal taiwan affairs
office; jiang zhu, member of the party working committee and deputy director of
the management committee of sip; hua liu, member of the party working committee
and deputy director of the management committee of sip; shan fu, chairman of
the board of directors of tot biopharm; jun liu, ceo and executive director of
tot biopharm; chunying huang , vice chairman and executive director of tot
biopharm, and yumin qiu, non-executive director of tot biopharm and partner of
advantech capital.
deputy director hua liu, said:
“the establishment of the global r&d center
of tot biopharm fully reflects the forward-looking layout of the enterprise for
innovation investment and its trust in the park environment. in the future, the
park will take the opportunity to build a biopharmaceutical technology
innovation center, make every effort to build a domestic first-class place of
origin for biopharmaceuticals, a world-class landmark area for
biopharmaceutical industry, thus creating a better development environment for
the park’s enterprises, including tot biopharm. we expect that tot biopharm’s global
r&d center, with its first-class talents, technologies, ideas and
management will accelerate the process of anti-cancer drug development and
continuously empower the park’s biopharmaceutical development.”
mr. shan fu, said:
“the
location of tot biopharm’s global r&d center in suzhou will help
consolidate tot biopharm’s advantages in the field of bio-innovative drugs, catering
to china and serving the whole world; it will also help strengthen tot biopharm’s
leading position in the field of adc drugs and promote the group’s innovative
drug development in china as well as the world. in the future, we will adhere
to two basic points, one is to focus on the domestic market and serve suzhou
well; the second is to adhere to tot biopharm’s long-standing commitment to
developing more products which enhance drug accessibility with large
indications and major varieties as the main target.”
dr.
jun liu stated,
“the completion of the global r&d center
will gather the company’s r&d advantages, focus on enhancing the strength
of innovative drug process development, and improve the fine management of
quality system, thus further accelerating the speed and quality of drug
development and better facilitating the cooperation with innovative drug
development companies. on the other hand, tot biopharm will make more effective
use of the completed factory 1 and factory 2 to expand its manufacture capacity
on a large scale, enhancing the flexibility of manufacture lines and preparing for
the implementation of more innovative drug manufacture.”
tot biopharm has an internationally competitive
anti-tumor drug development and manufacturing base in suzhou industrial park,
covering a total area of 50,000 square meters, with five phases of construction
planned. among them, the phase i anti-cancer drug plant and phase ii biologic
drug r&d industrialization base were completed which operated in 2012 and
2018, respectively. along with the continuous development of product pipeline,
the laboratories for drug r&d and testing in the plant could not meet the
r&d needs of the company’s diversified anti-tumor drugs, and the
construction of the global r&d center was then put on the agenda.
the global r&d center is expected to be
completed in 2023, with a total floor area of 25,000 square meters, and will
have the functions of early-stage r&d, process development, quality
research and headquarters office. among them, the r&d core experimental
area can accommodate 280-300 researchers, allowing research and process
development of multiple monoclonal drugs, adc drugs, oncolytic virus drugs and
special small molecule antitumor drugs to be carried out simultaneously, as
well as seamless connection with the production area. the localization of
r&d and production will also achieve collaborative and efficient drug
development throughout the entire process, thereby improving r&d efficiency
and cost advantages.
with the blueprint of “healthy china 2030” gradually
becoming a reality, china’s biopharmaceutical industry is flourishing. sip has
also placed biopharmaceutical industry as the “no. 1 industry”, gathering
high-end innovative resources and elements to build a world-class landmark area
for biopharmaceutical industry. tot biopharm has been rooted in sip for more
than 10 years and has steadily entered a harvest period. within a year, two
products were launched, one product has submitted a marketing application,
progress of adc (antibody drug conjugates) has been in the lead domestically,
and cdmo (contract development and manufacturing organization) services are in
full swing. the global r&d center is about to be in construction.
the establishment of the global r&d center
is an important milestone for tot biopharm, as well as a new starting point for
the company to deepen its layout of the biopharmaceutical industry. in the
future, tot biopharm will continue to uphold the corporate vision of “improving
the quality of life of global cancer patients with innovative technology”, and
continue to devote itself to the r&d of innovative drugs to empower the “china
innovative drug”.